BioSpace News Archive

Satellos Bioscience Inc., a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced that Frank Gleeson, Founder and CEO, will present live at VirtualInvestorConferences.com on December 16th.

Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced that it has been selected for addition to the Nasdaq Biotechnology Index and the iShares Biotechnology ETF.

Pulmatrix, Inc. announced that it has entered into a definitive agreement with certain institutional investors for the issuance and sale of an aggregate of 6,745 shares of convertible preferred stock and warrants to purchase up to an aggregate of 5,620,834 shares of common stock for gross proceeds of $6.75 million in a registered direct offering.

BridGene Biosciences, Inc., a biotechnology company using a unique chemoproteomic technology to discover and develop small molecules for high value, traditionally undruggable targets, today announced a research collaboration agreement with the Peter MacCallum Cancer Centre (Peter Mac), a world leading research, education, and treatment center in Melbourne, Australia.

Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, provided an overview of its cis-targeting platform and growing pipeline of highly differentiated precision immunotherapies.

180 Life Sciences Corp. today announced that it has entered into a new, exclusive global licensing agreement with The University of Oxford (“Oxford”) for the development and commercialization of HMGB1.

Arcadia (arcadia.io), the leading population health management and health intelligence platform, today released findings of its study published on medRxiv showing that current vaccines reduce the risk of long-COVID, even when administered up to 12 weeks after a COVID diagnosis.

MYND Life Sciences Inc. (“MYND” or the “Company”) (CSE: MYND) (OTC: MYNDF) is pleased to announce it has completed the National Phase filing of its Patent Cooperation Treaty (PCT) patent application, following on previously submitted provisional patent applications that describe: “A Method of Immune Modulation by Modulating a Specific Gene.”

Inventia Life Science has today announced the close of a US $25M Series B funding round, led by Blackbird Ventures.

LumiraDx (Nasdaq: LMDX) today announced a partnership with digital health non-profit Audere, to offer a self-collected COVID-19 nasal specimen collection kit that has been authorized for use with the LumiraDx SARS-CoV-2 RNA STAR Complete assay to process self-collected samples.